South Africa's TB Vaccine Breakthrough Could Save 8.5M Lives

Every 25 seconds, tuberculosis kills someone on our planet, but researchers at the University of Cape Town just brought us closer than ever to stopping this ancient killer.

African parliamentarians and health leaders from 15 countries witnessed major TB research breakthroughs at UCT's Lung Institute this week. The scientists are developing what could become the world's first truly effective TB vaccine for adolescents and adults, a medical achievement more than a century in the making.

The most promising candidate, called M72AS01E, has already proven 50 percent effective in preventing tuberculosis. That makes it the first vaccine in over 100 years to meet the World Health Organization's efficacy requirements for TB prevention.

Professor Mark Hatherill, director of the South African Tuberculosis Vaccine Initiative, shared the staggering potential. "TB kills one person every 25 seconds," he explained. "We urgently need vaccines that protect adolescents and adults because they are the main drivers of transmission."

The current BCG vaccine works well for infants and young children but loses effectiveness as they grow older. This new vaccine fills that critical gap, protecting the age groups most likely to spread the disease.

The Ripple Effect

The numbers tell a story of hope on a massive scale. Researchers project this vaccine could prevent up to 76 million TB cases worldwide over the next 25 years. That translates to approximately 8.5 million lives saved.

Phase three trials involving 20,000 participants across South Africa, Zambia, Malawi, Kenya, Indonesia and other countries are nearing completion. Associate Professor Angelique Kany Kany Luabeya, a lead investigator, said the crucial moment has arrived. "We are almost there. The question now is whether African countries are ready to roll out the vaccine once approval is granted."

Africa carries a disproportionate burden of TB infections globally. More than one million people die from the disease annually, with African nations among the hardest hit.

Beyond the vaccine itself, UCT researchers showcased other innovations during the visit. These include AI-supported digital stethoscopes, computer-assisted chest X-rays, and mobile TB case-finding units that can reach remote communities. Professor Keertan Dheda even unveiled research into inhaled TB vaccines delivered directly into the lungs through dry powder technology.

Professor Rod Dawson emphasized Africa's role in the solution. "This is an African story. We want African innovations developed, manufactured and delivered to African communities." That means building manufacturing capacity, strengthening regulatory systems, and preparing community awareness campaigns now.

Kenyan parliamentarian Stephen Mule left the visit with a renewed sense of purpose. "What we witnessed at UCT proves Africa has the scientific capacity to lead solutions for its own health challenges," he said.

The delegation urged governments to invest immediately in infrastructure and preparation so that when vaccine approval comes, African nations can begin saving lives without delay.